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Volume 50, Number 4 Abstracts 971CLI. Despite this, some patients presenting with CLI require traditional
lower extremity bypass procedures at some point for successful limb salvage.
To determine the proportion of patients requiring an open procedure, we
reviewed our one-year experience in CLI patients at a center committed to
endovascular approaches whenever possible.
Methods: We reviewed all patients presenting with CLI from January
1, 2007 to December 31, 2007. CLI was defined as ischemic rest pain, non
healing ulceration, or gangrene for which a major amputation was immi-
nently required. All patients underwent duplex and conventional angiogra-
phy prior to intervention. Endovascular treatments were favored as primary,
secondary, or tertiary treatments, if possible. If these failed or were impos-
sible, standard lower extremity bypasses were performed.
Results: Two hundred and fifty patients presented with primary,
secondary, or tertiary CLI over this one year period. Of these, 75 (30%) were
treated successfully with an endovascular intervention and 165 (66%) re-
quired standard lower extremity bypass. Of these 165 patients, 95 (58%)
were presenting with secondary, tertiary, or more CLI after failed previous
(one to five) procedures. The remaining 10 (4%) patients underwent com-
bined endovascular and open procedures.
Conclusions: Despite the initial enthusiasm and our belief that the
majority of patients presenting with CLI may be treated with endovascular
procedures, there exists a large cohort of patients that will ultimately require
standard open surgical procedures.
Outcomes of Endovascular and Open Treatment for Non-ruptured
Thoracic Aortic Aneurysms in New York State
Jonker FHW, Giacovelli JK, Muhs BE, Indes JE
Objectives: Endovascular thoracic aortic aneurysm repair (TEVAR)
has recently offered a less invasive alternative for open surgical repair of
non-ruptured thoracic aortic aneurysms (TAA). In this study, we evaluated
the trends and outcomes of open surgery and TEVAR for TAA in New York
State.
Methods: All patients admitted with TAA in New York State between
2000 and 2006 were extracted from the New York statewide planning and
research cooperative system (SPARCS) database. A diagnosis by Interna-
tional Classification of Diseases, 9th Revision coding of non-ruptured TAA
was required for inclusion. Trends in operative management and outcomes
were analyzed in patients undergoing open and endovascular repair.
Results: We identified 17,635 patients admitted with non-ruptured
TAA in New York State between 2000 and 2006. The annual admission rate
increased on average by 200 patients per year, from 1792 patients in 2000 to
3189 patients in 2006. Out of all patients with non-ruptured TAA, 4068
(23.1%) underwent surgical intervention, of which 3908 (96%) were treated
with open repair and 153 (3.8%) were treated with TEVAR (Fig). A
combined approach was performed in seven patients (0.2%), which were
excluded for further analysis. Elective repair was performed in 61.1%, urgent
repair in 15.9%, and emergency repair in 22.8%. There were no significant
differences in urgency of the procedure between the open repair and TEVAR
groups. The in-hospital mortality did not differ significantly and was 4.8%
(n 189) in the open repair group, and 5.2% (n 8) in the TEVAR group
(Odds Ratio [OR]: 0.92, 95% Confidence Interval [CI]: 0.45 - 1.91, P 
.843). TEVAR appeared to lower postoperative morbidity, in particular
cardiac complications, which occurred in 18.6% (n 725) after open repair
vs. 3.9% (n 6) after TEVAR (OR: 5.58, 95% CI: 2.46 - 12.7, P .0001).
Patients that were treated with TEVAR were more frequently discharged to
home than patients treated with open repair (51.6% vs. 37.3%, P  .0003),
and had a shorter length of stay (10.3 days vs. 13.7, P  .015).
Conclusions: The number of patients admitted with non-ruptured
TAA is increasing in New York State. The utilization of endovascular repair
is increasing as well, which is associated with reduced morbidity and shorter
hospital stays, while the mortality appears similar for both groups.Temporal Changes of Aortic Neck Morphology in Small Aneurysms
(AAA) Under CT Surveillance: Implications in the EVAR Era
Propper BW, Gifford SM, Burkhardt GE, Zarzabal LA, Rasmussen TE,
Clouse WD
Objectives: Although suitable aortic neck morphology is critical to suc-
cessful endovascular aneurysm repair (EVAR), little is known regarding changes
in neck length and neck diameter as aneurysms expand. The objective of this
study is to describe morphologic changes in the aortic neck of small abdominal
aortic aneurysms (AAA)under computed tomography (CT) surveillance, and to
examine their implications for clinical decision making.
Methods: A retrospective review of patients with infrarenal AAA 3 cm
to 5 cm was conducted. All patients had two CT scans separated by at least
six months. Neck diameter (proximal and distal) and length from lowest
renal to proximal aneurysm were measured along with maximum aneurysm
diameter in scans separated by time. Univariate log-rank analysis of potential
factors affecting neck growth patterns was performed.
Results: Sixty patients were identified. Average time between CT scans
was 3.8 years (median, 3.4 years; range, 0.75-9.6 years). During this time,
increases in proximal and distal neck diameters were 1.1 mm (SD 2.2), 0.28
mm/yr; and 1.0 mm (SD 3.0), 0.26 mm/yr, respectively. Average AAA
growth was 1.6mm/yr.Mean neck length decreased by 4mm (SD 11), thus
shortening by 1mm/yr. Patients with AAA diameters less than 4 cm at initial
read (n  34) had aneurysm expansion of 1.3 mm/yr and neck shortening
of 2 mm/yr. Those with initial diameters of greater than 4 cm (n 26) had
diameter expansion of 1.8 mm/yr and neck shortening of 0.3 mm/yr. Neck
length less than 15 mm was present in 10 (17%) patients at initial imaging.
Of the remaining 50 patients, 8% (n 4) had aortic neck length shortening
to less than 15mm during the surveillance period. However, 11 patients had
neck lengths of 15 mm to 20 mm at initial read and four (36%) shortened to
less than 15 mm. Medications were found to have no association with neck
shortening (beta-blockade [P  .69], ace inhibitors [P  .31]; statin
medication [P .53]). Diabetes mellitus correlated with slower rate of neck
shortening (P  .001).
Conclusions: As aneurysms expand, neck length is reduced by one
millimeter per year while change in neck diameter is negligible. During surveil-
lance, few patients with appropriate EVAR neck anatomy lose neck length
prohibiting later EVAR. However, those with marginal neck lengths may have
increased risk of losing suitability and thus warrant a more vigilant approach.
Outcome of Treatment of Peripheral Arterial Disease (PAD) by Insurer
Status in New York State
Drujski ML, O’Brien-Irr MS, Dosluoglu HH, Harris LM
Objectives: Type or lack of insurance may impact access to care,
treatment provided, and outcome. We evaluated trends for surgical manage-
ment of all peripheral arterial disease (PAD) hospital admissions by insurer
over a seven-year period in New York State (NYS).
Methods: Health Administration of New York State (HANYS) data by
insurer was obtained for the years 2001 to 2007 and is listed in Table I. Data
from 2001and 2002were averaged and used as a baseline fromwhich themean
change in percentage was calculated for the years 2004 to 2007. Analysis was
completed by analysis of variance (ANOVA). Significance was at the 0.05 level.
Results: Themean change in percentage for procedure, limb salvage, and
indication are presented in table II. Open procedures declined for all except the
uninsured (UI) (P .001). Endovascular intervention (EVI) increased dramat-
ically and was highest for Medicaid (P .03). Reductions in amputation were
seen for all except the UI (P .04). Admission for gangrene increased for the
UI but declined for all others (P .001; Table II).
Conclusions: Decline in admission for gangrene, open procedures, and
amputations were comparable among those with insurance and, in fact, were
highest in theMedicaid population, dispelling concerns that care of the indigent
maybe inferior. In contrast,UI patients experienced an increase in admission for
gangrene, increase in open procedures, less substantial increase in EVI than
insured patients, and a reduction in limb salvage. These data may indicate more
advanced disease that is non-amenable to EVI and may be related to delayed
presentation from financial concerns. Extending benefits to the small percent-
age of UI may improve access and ultimately outcome.
Table I. Diagnostic codes and procedures
Diagnostic Codes N Procedures N
440.21-Claudication: 14,888 39.25-Aorto-Bi-Fem BPG: 6,048
440.22- Rest Pain: 7,077 39.29- Fem-Pop, Distal BPG: 37,644
440.23- Ulcer: 10,177 39.50-Angioplasty/Atherectomy: 53,258
440.24- Gangrene: 20,344 39.90-Peripheral Stent: 32,237
84.15, 84.17- BKA/AKA: 24,740
BKA/AKA, Below the knee amputation/above the knee amputation; BPG,
bypass grafting.
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Insurer
Open
Procedure EVI
AKA/
BKA
Admission
For
Gangrene
Private pay (PP) 21% 221% 162% 214% 213%
Medicare 68% 217% 1101% 211% 25%
Medicaid 9% 224% 1115% 214% 227%
Uninsured (UI) 1% 18% 138% 17% 135%
Significance P  .001 P  .03 P  .04 P  .001
AKA/BKA; Above the knee amputation/below the knee amputation; EVI,
endovascular intervention.
Hydrogen Sulfide Prevents Ischemia-Reperfusion Injury in Muscle
even when Delivered in the Post-ischemic Period
Henderson PW, Singh SP, Weinstein AL, Nagineni V, Spector JA
Objectives: Ischemia-reperfusion injury (IRI) is an unavoidable con-
sequence of revascularization following acute vascular occlusion. Hydrogen
sulfide (H2S) is now recognized as an endogenous signaling molecule, and
recent work from our lab has shown that H2S mitigates IRI in muscle when
delivered prior to the onset of ischemia. The purpose of this study was to
determine whether H2S confers a similar protective effect when delivered
after an ischemic event has occurred.
Methods:Nine C57/BL6 mice underwent three hours of tourniquet-
induced hind limb ischemia and were randomized to three groups: no H2S,
10M intravenous H2S delivered one minute prior to reperfusion, and
10M H2S delivered 20 minutes prior to reperfusion. After three hours of
reperfusion, the gastrocnemius and soleus muscles were harvested bilater-
ally. Sections were stained with hematoxylin and eosin (H&E) and subjected
to a terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assay. Values are reported as mean SE, and student t tests were
performed compared to non-H2S-treated mice. Statistical significance was
set at P  .05.
Results:Upon histologic examination, ischemic tissue from non-H2S-
treated mice had architectural changes including extracellular edema and
intracellular vacuolization; tissue from mice treated with H2S one minute
prior to reperfusion was similar in appearance (Fig). Ischemic tissue from
mice treated with H2S 20 minutes prior to reperfusion showed no evidence
of architectural changes. Non-ischemic tissue treated with H2S was not
different in appearance from non-ischemic, non-treated tissue. The percent-
age of apoptotic cells was significantly reduced by treating mice with H2S 20
minutes prior to reperfusion, but not when H2S was delivered one minute
prior (18.1%  11.0% in non-HS-treated mice, 1.8%  1.4% [P  .026] in
mice treated with H2S 20 minutes prior to reperfusion, and 16.0%  7.7%
[P  .771] in mice treated with H2S one minute prior to reperfusion).
Conclusions: After an ischemic insult has occurred, H2S protects
against IRI when delivered 20 minutes, but not one minute, prior to
reperfusion. This suggests the mechanism by which H2S functions requires
equilibration prior to reperfusion. The absence of injury in non-ischemic
H2S-treated tissue suggests that H2S is non-toxic at the dose tested in this
study (10 M). We conclude that H2S may have clinical application as a
component of therapeutic revascularization regimens.
Endothelial Cells with Eph B4 Heterozygous Knockdown: A Novel
Model for Vein Graft Adaptation
Feigel A, Muto A, Fancher T, et al
Objectives: Vein graft adaptation (VGA) is characterized by vein wall
thickening, a complex process requiring cell proliferation and migration. We
have previously shown that VGA is also associated with loss of the venous
determinant Eph-B4. To study molecular mechanisms that mediate VGA,
we developed a novel in vitro model of VGA.Methods: Aortic interposition grafts were examined using veins from
wild type (WT) and Eph-B4 heterozygous knockout (Eph-B4-KO) mice.Endothelial cells (EC) were isolated from both WT and Eph-B4-KO mice.
Cell proliferation was directly counted. Quantitative polymerase chain reac-
tion (qPCR) was used to evaluate basal mRNA expression. Western blot was
used to evaluate protein levels. Cell migration was evaluated using a Boyden
chamber.
Results: Vein grafts from Eph-B4-KO mice had 50% increased intimal
thickness compared with vein grafts from WT mice (P  .01). Under basal
conditions, Eph-B4-KO cells proliferated 41% more slowly than WT EC
(P  .029), and 43% more slowly when stimulated with Ephrin-B2/Fc.
Basal protein expression of Akt was 29% higher, and vascular endothelial
growth factor (VEGF)-A was 28% lower in Eph-B4-KO cells compared with
WT EC. Under direct stimulation, levels of phosphorylated AKT and
phosphorylated ERK 1/2 were greater in Eph-B4-KO cells. qPCR con-
firmed 49% less VEGF-A mRNA expression in Eph-B4-KO cells. Eph-
B4-KO cells had 60% reduced cell migration in response to Ephrin-B2/Fc
(P  .005).
Conclusions: EC isolated from Eph-B4-KO mice serve as a novel in
vitro model of VGA. This model suggests that reduced Eph-B4 expression
during VGAmay bemediated by upstream signals such as VEGF-A as well as
downstream pathways such as Akt.
The Effect of Tortuosity on Five Different Cerebral Protection Devices
in an Ex-vivo Model
Shah AR, Lipsitz EC, Scher L, et al
Objectives: To compare the efficacy and ease of deployment for five
currently available cerebral protection devices at varying degrees of tortuos-
ity.
Methods: An ex-vivo study using procured canine carotid arteries was
performed using an open flow model with three anatomical variants (non-
tortuous, mildly tortuous, and severely tortuous) and two embolic particle
sizes (250 and 425 microns). Cerebral protection devices (Accunet
[Guidant Corporation, Santa Clara, Calif], Angioguard [Cordis, Miami
Lakes, Fla], Emboshield [Abbott Laboratories, Abbott Park, III], Filterwire
EZ [Boston Scientific Corporation, Natick, Mass], and SpideRX [ev3, Inc,
Plymouth, Minn]) were placed under fluoroscopy at the point of maximal
inflection in the case of tortuous vessels. A total of 1.5 mg ( 0.05 mg) of
polyvinyl alcohol (PVA) particles of either size was injected into the carotid
system proximal to each of five protection devices at each of the three
degrees of tortuosity. Particles captured by the filters were weighted and
compared with the weight of the particles collected in the effluent filter (not
captured). The time taken to deploy each device at this position was
recorded.
Results: The percent capture for each of the five filters at each degree
of tortuosity using 425 micron particles is shown in the Fig. Similar results
were obtained for the 250 micron particles. Filterwire EZ and SpiderX were
deployed within the 26 to 27 second range. All others were deployed
between 30 and 36 seconds.
Conclusions: No filter completely prevented embolization. Filterwire
EZ, Accunet, and Angioguard exhibited the highest capture rates in straight
anatomy. Angioguard was the most efficacious filter in tortuous anatomy.
Increasing tortuosity had a significant negative impact on all filters. Filter-
wire EZ and SpiderX had the best trackability in tortuous vessels using this
model.
Mechanical Stimulation of HUVEC: Different Flow Patterns have
Differential Effects on TF Expression
Nixon AM, Rochier A, Yamashita N, Sumpio BE
Objectives: Human umbilical vein endothelial cells (HUVECs) are
known to respond differentially to various mechanical stimuli, and these
different responses maybe involved in atherogenesis. Here we investigated
the differential effects of different flow patterns, such as laminar flow (LF)
and orbital shear stress (OSS), on the expression of tissue factor (TF).
Methods:HUVECs were seeded on fibronectin coated glass slides and
selectively in the periphery of gelatin coated culture dishes. When HUVECs
on slides reached confluence, they were exposed to two, four, or six hours of
LF (14 dynes/cm2). HUVECs in culture dishes were exposed to the same
